WallStSmart

Merit Medical Systems Inc (MMSI)vsNovartis AG ADR (NVS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 3533% more annual revenue ($57.36B vs $1.58B). NVS leads profitability with a 17.5% profit margin vs 9.2%. MMSI appears more attractively valued with a PEG of 1.67. MMSI earns a higher WallStSmart Score of 54/100 (C-).

MMSI

Buy

54

out of 100

Grade: C-

Growth: 6.7Profit: 6.0Value: 3.3Quality: 8.0
Piotroski: 4/9Altman Z: 2.46

NVS

Hold

48

out of 100

Grade: D+

Growth: 4.0Profit: 9.0Value: 2.7Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MMSISignificantly Overvalued (-44.8%)

Margin of Safety

-44.8%

Fair Value

$56.16

Current Price

$84.16

$28.00 premium

UndervaluedFair: $56.16Overvalued
NVSSignificantly Overvalued (-68.3%)

Margin of Safety

-68.3%

Fair Value

$95.56

Current Price

$161.52

$65.96 premium

UndervaluedFair: $95.56Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MMSI2 strengths · Avg: 8.0/10
Price/BookValuation
3.0x8/10

Reasonable price relative to book value

EPS GrowthGrowth
20.4%8/10

Earnings expanding 20.4% YoY

NVS4 strengths · Avg: 9.5/10
Market CapQuality
$303.67B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.3%10/10

Strong operational efficiency at 34.3%

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

Areas to Watch

MMSI2 concerns · Avg: 4.0/10
PEG RatioValuation
1.674/10

Expensive relative to growth rate

P/E RatioValuation
38.4x4/10

Premium valuation, high expectations priced in

NVS4 concerns · Avg: 4.0/10
P/E RatioValuation
30.7x4/10

Premium valuation, high expectations priced in

Price/BookValuation
8.2x4/10

Trading at 8.2x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : MMSI

The strongest argument for MMSI centers on Price/Book, EPS Growth.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.

Bear Case : MMSI

The primary concerns for MMSI are PEG Ratio, P/E Ratio.

Bear Case : NVS

The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.

Key Dynamics to Monitor

MMSI carries more volatility with a beta of 0.51 — expect wider price swings.

MMSI is growing revenue faster at 9.5% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MMSI scores higher overall (54/100 vs 48/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merit Medical Systems Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, intensive care, and endoscopy. The company is headquartered in South Jordan, Utah.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?